参考文献/References:
[1] SELBY R, ABDULREHMAN J. Antiphospholipid antibodies and the antiphospholipid syndrome: from coagulation to the clinic [J]. Journal of Applied Labora-tory Medicine, 2022, 7(1): 373-378.
[2] 杨荣荣,张萍.外周血液狼疮抗凝物质比值及T细胞免疫球蛋白黏蛋白分子3水平与孕早期复发性流产的相关性研究[J].现代检验医学杂志, 2020, 35(1): 60-64. YANG R R, ZHANG P. Study on the relationship between ratio of lupus anticoagulant and levels of T-cell immuno-globulin-mucin molecule 3 in peripheral blood and recurrent abortion in early pregnancy[J]. Journal of Modern Laboratory Medicine, 2020, 35(1): 60-64.
[3] FAVALORO E J, PASALIC L, SELBY R. Testing for the lupus anticoagulant: the good, the bad, and the ugly[J]. Research and Practice in Thrombosis and Haemostasis, 2024, 8(3): 102385.
[4] 程航,冀续峰,刘海艳,等.凝血因子的多点稀释分析(MDA)方法在筛查病理性抗凝物中的应用[J].中国实验诊断学, 2019, 23(2): 243-247. CHENG H, JI X F, LIU H Y, et al. The application of multi-point dilution analysis(MDA)of coagulation fac-tors in screening pathological anticoagulants[J]. Chinese Journal of Laboratory Diagnosis, 2019, 23(2): 243-247.
[5] DEVREESE K M J, DE GROOT P G, DE LAAT B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation[J]. Journal of Thrombosis and Haemostasis, 2020, 18(11): 2828-2839.
[6] 中国研究型医院学会血栓与止血专业委员会.狼疮抗凝物检测与报告规范化共识[J].中华检验医学杂志, 2024, 47(2): 129-135. Chinese Society on Thrombosis and Hemostasis. Con-sensus on normalized testing and reporting of lupus anticoagulant[J]. Chinese Journal of Laboratory Medi-cine, 2024, 47(2): 129-135.
[7] 中国研究型医院学会血栓与止血专委会.活化部分凝血活酶时间延长混合血浆纠正试验操作流程及结果解读中国专家共识[J].中华检验医学杂志,2021,44(8):690-697. Chinese Society on Thrombosis and Hemostasis. Chinese expert consensus on operation procedure and result inter-pretation of APTT mixing test[J]. Chinese Journal of Lab-oratory Medicine, 2021, 44(8): 690-697.
[8] 中华人民共和国国家卫生健康委员会. WS/T 220-2021:凝血因子活性测定技术标准[S].(2022-01-01)https://www.nhc.gov.cn/wjw/c100175/202109/4b2bf876c54f491bb-2fe5bb55015e9ed/files/1645425533375_73170.pdf. National Health Commission of the People’s Republic of China. WS/T 220-2021: Technical standard for coagula-tion factor activity assay[S].(2022-01-01)https://www.nhc. gov.cn/wjw/c100175/202109/4b2bf876c54f491bb2fe5b-b55015e9ed/files/1645425533375_73170.pdf.
[9] 颜楠,刁艳君,韩峰,等.凝血相关检测常见干扰因素分析与探讨[J].临床血液学杂志, 2023, 36(10): 693-696. YAN N, DIAO Y J, HAN F, et al. Analysis and discussion of common interfering factors in coagulation related test[J].Journal of Clinical Hematology, 2023, 36(10): 693-696.
[10] 王甜甜,房云海,王杰,等.凝血因子Ⅴ抑制物致多项凝血因子活性假性降低[J].临床检验杂志, 2021, 39(8): 605-606, 613. WANG T T, FANG Y H, WANG J, et al. Pseudo-reduc-tion in the activity of multiple coagulation factors caused by coagulation factor V inhibitors[J]. Chinese Journal of Clinical Laboratory Science, 2021, 39(8): 605-606, 613.
[11] 颜楠,刁艳君,韩峰,等.FⅧ抑制物与狼疮抗凝物对凝血因子检测结果的影响[J].临床检验杂志, 2023, 41(8): 572-574. YAN N, DIAO Y J, HAN F, et al. The influence of FⅧ inhibitors and lupus anticoagulants on the detection results of coagulation factors[J]. Chinese Journal of Clinical Laboratory Science, 2023, 41(8): 572-574.
[12] FAVALORO E J, PASALIC L. Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin! [J]. Research and Practice in Thrombosis and Haemostasis, 2022, 6(2): e12689.
[13] DODIG S, ?EPELAK I. Antiphospholipid antibodies in patients with antiphospholipid syndrome[J]. Biochemia Medica, 2024, 34(2): 020504.
[14] SHOENFELD Y, MERONI P L, GERSHWIN M E. Auto-antibodies[M]. Third Edition. Amsterdam: Elsevier, 2014.
[15] 张家红,王金行,夏楠,等.活化部分凝血活酶时间检测狼疮抗凝物的灵敏度及其相关性[J].中国医科大学学报, 2021, 50(6): 502-506. ZHANG J H, WANG J H, XIA N, et al. Sensitivity and correlation of activated partial thromboplastin time to lupus anticoagulants[J]. Journal of China Medical Uni-versity, 2021, 50(6): 502-506.
[16] KUMAR S, SUMMERS B, BASORE K, et al. Cryo-EM structure and functional basis of prothrombin rec-ognition by a type I antiprothrombin antiphospholipid antibody[J]. Blood, 2024, 143(19): 2005-2011.
[17] 白伊娜,孟菁菁,赵久良,等.抗磷脂综合征中非标准抗磷脂抗体的诊断价值和风险预测[J].中华临床免疫和变态反应杂志, 2023, 17(5): 395-406. BAI Y N, MENG J J, ZHAO J L, et al. Diagnostic value and risk prediction of non-criteria antiphospholipid anti-bodies in antiphospholipid syndrome[J]. Chinese Journal of Allergy & Clinical Immunology, 2023, 17(5): 395-406.
[18] 张丽华,谢智强,庄和,等.凝血因子Ⅷ抑制物阳性血友病患者APTT纠正试验结果分析[J].中国实验血液学杂志, 2023, 31(6): 1791-1796. ZHANG L H, XIE Z Q, ZHUANG H, et al. Analysis of APTT mixing test results in factor Ⅷ inhibitor-pos-itive hemophilia patients[J]. Journal of Experimental Hematology, 2023, 31(6): 1791-1796.
[19] 李刚,陈振萍,甄英姿,等.血友病 A 患儿血浆纠正实验与凝血因子Ⅷ抑制物相关性研究[J].中华检验医学杂志, 2015(7): 480-483. LI G, CHEN Z P, ZHEN Y Z, et al. Correlation between mixed APTT test and FⅧ inhibitor in children with hemophilia A[J]. Chinese Journal of Laboratory Medicine, 2015(7): 480-483.
[20] 张家红,夏楠,王金行,等.3种狼疮抗凝物检测方法的临床应用价值评价[J].中国医科大学学报, 2021, 50(2): 97-101. ZHANG J H, XIA N, WANG J H, et al. Evaluation of the clinical application value of three lupus anticoag-ulant detection methods[J]. Journal of China Medical University, 2021, 50(2): 97-101.
[21] 王秀荣,曲岩,石艳丽.3种狼疮抗凝物检测方法的应用评价[J].实验室检测,2025,3(11):47-49. WANG X R, QU Y, SHI Y L. Evaluation of the applica-tion of three lupus anticoagulant detection methods[J]. Laboratory Testing, 2025, 3(11): 47-49.